NEW YORK (Reuters Health)—Changes in atmospheric and environmental factors may contribute to organ-specific disease exacerbation in patients with systemic lupus erythematosus (SLE), according to a new study. The study found “strong associations between atmospheric variables and fine particulate matter concentration over the 10 days prior to a patient visit and organ-specific lupus flares at the…
Articles by Natasha Yetman
Google Signs Healthcare Data & Cloud Computing Deal with Ascension
(Reuters)—Alphabet Inc.’s Google signed its biggest cloud computing customer in healthcare yet, according to an announcement on Monday, gaining with the deal datasets that could help it tune potentially lucrative artificial intelligence tools. The Wall Street Journal earlier reported Google teaming up with Ascension to collect personal health-related information of millions of Americans across 21…
Trump Nominates MD Anderson Oncologist as U.S. FDA Commissioner
(Reuters)—U.S. President Donald Trump has nominated Stephen Hahn, MD, chief medical executive of the University of Texas MD Anderson Cancer Center, to lead the U.S. Food and Drug Administration (FDA), the White House said on Friday. Dr. Hahn, a radiation oncologist who has been at MD Anderson in Houston since 2015, if confirmed would follow…
Iguratimod May Hold Promise for Treating Autoimmune Disease
NEW YORK (Reuters Health)—Iguratimod, a disease-modifying drug marketed in China and Japan, appears to be effective in treating rheumatoid arthritis (RA) and possibly other autoimmune diseases, while protecting against adverse bone effects, researchers from China say. Iguratimod is a methane sulfonanilide compound that influences several anti-inflammatory and immune-modulatory pathways and has an anabolic effect on…
Trump Administration Proposes Changes to Healthcare Anti-Kickback Rules
(Reuters)—The Trump administration has proposed changes to federal anti-kickback provisions that restrict the kinds of patient referrals doctors can make, saying it will improve healthcare coordination and foster payments based on the quality of care. The plan will change how the U.S. Department of Health and Human Services (HHS) enforces the Physician Self Referral Law,…
One-Quarter of Every U.S. Healthcare Dollar Wasted
(Reuters Health)—About a quarter of the dollars spent on healthcare in the U.S. may be wasted, a new analysis suggests. Six types of waste in healthcare could be costing as much as $935 billion annually, according to the study published in JAMA.1,2 The biggest source of waste is “administrative complexity,” says the study’s lead author…
Mortality from Anti-neutrophil Cytoplasmic Autoantibody-Associated Vasculitis Falling Slightly
NEW YORK (Reuters Health)—Mortality rates in patients with antineutrophil cytoplasmic autoantibody-associated vasculitis (AAV) decreased from 1999 to 2017, according to records from the Centers for Disease Control and Prevention (CDC). “The mortality attributed to several rare diseases [e.g., hypersensitivity pneumonitis] has increased in recent years,” Alexander W. Steinberg, MD, from Saint Joseph Hospital, Denver, tells…
Humira, Rituxan Top List of U.S. Drugs with Biggest Price Increases
NEW YORK (Reuters)—AbbVie Inc.’s rheumatoid arthritis drug Humira (adalimumab) and Roche Holding AG’s cancer drug Rituxan (rituximab) topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed.1 The price hikes were more than twice the rate of…
Transbronchial Lung Cryobiopsy a Valid Diagnostic Option in Interstitial Lung Disease
NEW YORK (Reuters Health)—Transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB) had a high level of agreement for diagnosing interstitial lung disease in the first comparative study. “These data suggest that TBLC, when done by an experienced proceduralist, is a valid first-line minimally invasive diagnostic tool for patients with interstitial lung disease deemed to…
Nintedanib Slows Lung Deterioration in General Fibrosing Interstitial Lung Disease
NEW YORK (Reuters Health)—Nintedanib dramatically slows lung deterioration in patients with progressive fibrosing interstitial lung diseases, according to a new randomized study.1 Nintedanib has already been shown to be effective against idiopathic pulmonary fibrosis (IPF). The new trial, funded by the manufacturer, Boehringer Ingelheim, and presented t the European Respiratory Society International Congress 2019 in…
- « Previous Page
- 1
- …
- 19
- 20
- 21
- 22
- 23
- …
- 97
- Next Page »